The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy

Abstract

Cervical carcinoma is one of the most common cancers among women globally. Histone deacetylase inhibitors (HDACIs) constitute anticancer drugs that, by increasing the histone acetylation level in various cell types, induce differentiation, cell cycle arrest, and apoptosis. The aim of the current review is to study the role of HDACIs in the treatment of cervical cancer. A literature review was conducted using the MEDLINE and LIVIVO databases with a view to identifying relevant studies. By employing the search terms “histone deacetylase” and “cervical cancer”, we managed to identify 95 studies published between 2001 and 2023. The present work embodies the most up-to-date, comprehensive review of the literature centering on the particular role of HDACIs as treatment agents for cervical cancer. Both well-established and novel HDACIs seem to represent modern, efficacious anticancer drugs, which, alone or in combination with other treatments, may successfully inhibit cervical cancer cell growth, induce cell cycle arrest, and provoke apoptosis. In summary, histone deacetylases seem to represent promising future treatment targets in cervical cancer.

The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia

“…Epigenetic modifications have been in the spotlight of cancer research in recent years, as a deeper understanding of their implication in tumorigenesis holds the key to early detection and precise diagnosis of tumors, the estimation of patients' prognosis, and the development of novel, personalized, and ever more effective therapeutic interventions. DNA and RNA methylation mechanisms, histone modifications, and expression of non-coding RNAs constitute fundamental processes behind carcinogenesis and tumorsuppression [103][104][105][106][107][108][109]. Extensive research has emphasized the role of DAXX and HJURP, among other biomolecules implicated in epigenetic mechanisms, in the pathogenesis of a great variety of neoplasms.…”

The Role of Receptor–Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors

“…For example, methylation of the SSTR1, SSTR2, and SSTR5 gene promoters may influence their expression in cancer cells [ 14 , 37 ]. The use of histone deacetylase inhibitors may also affect the expression of SSTR receptors [ 71 ].…”

Deacetylation of Histones and Non-histone Proteins in Inflammatory Diseases and Cancer Therapeutic Potential of Histone Deacetylase Inhibitors

“…Because of the crucial roles of HDACs in cancer, HDAC inhibitors (Table 1 ) have been proposed as anti-cancer agents [ 101 - 105 ]. For instance, the class I HDAC inhibitor valproic acid has been shown to enhance the effectiveness of chemotherapy agents in human melanoma cells [ 106 ]. Similarly, the class I HDAC inhibitor domatinostat has been shown to sensitize pancreatic cancer cells to chemotherapy by exerting its effect on the transcription factor FOXM1 [ 107 ].…”